V

Vapotherm Inc
F:VA21

Watchlist Manager
Vapotherm Inc
F:VA21
Watchlist
Price: 2.976 EUR Market Closed
Market Cap: 137.6m EUR

Vapotherm Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Vapotherm Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
V
Vapotherm Inc
F:VA21
Research & Development
-$14.2m
CAGR 3-Years
6%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Research & Development
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Boston Scientific Corp
NYSE:BSX
Research & Development
-$1.9B
CAGR 3-Years
-14%
CAGR 5-Years
-11%
CAGR 10-Years
-9%
Stryker Corp
NYSE:SYK
Research & Development
-$1.5B
CAGR 3-Years
-7%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Abbott Laboratories
NYSE:ABT
Research & Development
-$2.9B
CAGR 3-Years
-1%
CAGR 5-Years
-5%
CAGR 10-Years
-8%
Intuitive Surgical Inc
NASDAQ:ISRG
Research & Development
-$1.2B
CAGR 3-Years
-15%
CAGR 5-Years
-16%
CAGR 10-Years
-20%
No Stocks Found

Vapotherm Inc
Glance View

Market Cap
137.6m EUR
Industry
Health Care

Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.

VA21 Intrinsic Value
Not Available

See Also

What is Vapotherm Inc's Research & Development?
Research & Development
-14.2m USD

Based on the financial report for Dec 31, 2023, Vapotherm Inc's Research & Development amounts to -14.2m USD.

What is Vapotherm Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-10%

Over the last year, the Research & Development growth was 30%. The average annual Research & Development growth rates for Vapotherm Inc have been 6% over the past three years , -10% over the past five years .

Back to Top